Outlines a comprehensive, evidence-based approach to coordinating psychopharmacological and psychotherapeutic treatments Cognitive Behavioral Psychopharmacology takes an evidence-based approach to demonstrating the advantages of biopsychosocial integration in interventions for the major psychiatric diagnoses. It is the first and only book to translate the current evidence for cognitive behavioral, psychosocial, and pharmacologic approaches to mental health disorders into clear guidance for clinical practice. There is a burgeoning movement in mental health to acknowledge the entire person’s functioning across physical, psychological and social spheres, and to integrate medical as well as psychological and social interventions to address the entire spectrum of presenting problems. This book bridges a gap in the professional mental health literature on the subject of standalone versus combined treatment approaches. It reviews the current state of integrative care, and makes a strong case that optimal outcomes are best achieved by an awareness of how and why the cognitive-behavioral aspects of prescribed medical and psychological interventions influence treatment. Each disorder-specific chapter is authored by a prescriber and psychotherapist team who consider all the evidence around treatments and combinations, providing outcome conclusions and concise tables of recommended front-line interventions. Provides a biopsychsocial perspective that integrates the medical, psychotherapeutic, family, and community aspects of the therapeutic process Brings together and compares the current evidence for and against treatments that combine psychopharmacology and cognitive behavioral psychotherapy for major psychiatric diagnoses Outlines an evidence-based approach to determining which combination of treatments is most appropriate for each of the major psychiatric diagnoses Describes, in a way that is accessible to both prescribers and therapists, when and how cognitive behavioral therapy can be integrated into pharmacotherapy The book will appeal to a wide range of mental health professionals, including psychologists, psychiatrists, clinical social workers, licensed professional counselors, marriage and family therapists, and addictions counselors. It also will be of interest to primary care physicians and nurse practitioners who work side by side with mental health professionals.

The Clinician's Guide to Cognitive-Behavioral Therapy for Childhood Obsessive-Compulsive Disorder brings together a wealth of experts on pediatric and adolescent OCD, providing novel cognitive behavioral strategies and considerations that therapists can immediately put into practice. The book provides case studies and example metaphors on how to explain exposure models to children in a developmentally appropriate manner. The book also instructs clinicians on how to use symptom information and rating scales to develop an appropriate exposure hierarchy. The book is arranged into two major sections: assessment and treatment of childhood OCD and special considerations in treating childhood OCD. Each chapter is structured to include relevant background and empirical support for the topic at hand, practical discussion of the nature and implementation of the core component (such as exposure and response prevention, cognitive therapy, psychoeducation and more), and a case illustration that highlights the use of a particular technique. - Provides the strong theoretical foundation required to successfully implement treatment - Highlights the use of particular intervention techniques through case studies - Provides CBT strategies for anxiety, tic disorders, trichotillomania, ADHD and disruptive behaviors - Includes strategies for treatment of patients who are initially non-responsive to CBT - Encourages individualization of evidence-based and clinically-informed principles for each patient - Reviews what to do if/when OCD remits and/or returns - Provides details on differentiation OCD symptoms from anxiety and other psychopathology

Behavioral Pharmacology of Drug Abuse: Current Status, Volume 93 provides an update on our current understanding of animal and human behavioral pharmacology in major classes of drugs of abuse, including nicotine, alcohol, opioids, psychostimulants, and hallucinogens, drug-environment interactions, neurochemical mechanisms and medications developments. This volume updates the field of behavioral pharmacology based on new knowledge gained in the past decade. - Provides accurate and updated reviews from selected experts on covered topics - Presents useful graphic material for ease of reading - Covers a wide range of topics that are highly integral to offer a panoramic view of the field of behavioral pharmacology

The most comprehensive guide to cognitive-behavioral therapy (CBT) with clients in crisis is now in a significantly revised fourth edition with 75% new material. Over 15 years of clinical and research advances are reflected in fully updated chapters on evidence-based brief strategies for helping people cope in highly stressful situations. From leading experts, the book addresses suicide prevention, crises related to mental and physical health problems, child and family crises, and exposure to disasters and mass or community violence. Vivid case material illustrates what the interventions look like in action and how to tailor them to individual clients' needs. New to This Edition *Chapter on clinician self-care. *Chapters on managing the involuntary hospitalization process, working with psychosis in inpatient settings, intervening with clients at risk for mass violence, and more. *Chapters retained from the prior edition are all updated or rewritten to incorporate current data, clinical strategies, and assessment tools. *All of the case examples are new.

The molecular genetics of the cholinergic system including both muscarinic and nicotinic acetylcholine receptors, cholinesterases, acetylcholine synthesis and release have provided significant insights into potential targeting for pharmacological intervention. Cholinergic drugs are being used or evaluated for the treatment of diseases. Thus, this volume aims to broaden our understanding of the current state of cholinergic mechanisms to enable implementation of novel approaches for the development of more effective treatments.

vii Drugs and sex are two topics about which most people have strong opinions and weak understanding. Knowledge of each can be gained in many ways, all with associated rewards and risks. Like all textbooks, this one was written in the belief that reading can foster learning. The book is intended to introduce principles of behavioral pharmacology to readers with little or no knowledge of the discipline but with an interest in how drugs affect human behavior. Gleaning anything of value from the text requires two things from the reader. The first is a willingness to accept an analysis of drug effects that shares little with folklore or common sense no tions of drug action. The second is a willingness to accept the fact that the behavioral effects of drugs are complex and depend upon a sizable number of pharmacological and behavioral variables. Unless one is aware of these factors and how they determine a drug's actions, the behavioral effects of drugs can be neither pre dicted nor meaningfully explained. If it does nothing else, this volume will make it obvious that the behavioral effects of drugs are lawful and can be predicted and understood on the basis of well-established relations between empirical phenomena. De scribing these relations and exploring how they allow behavioral ix x PREFACE pharmacologists to make sense of drug effects that are otherwise incomprehensible was a major goal in preparing the text.

The Science of Cognitive Behavioral Therapy describes the scientific approach of CBT, reviews the efficacy and validity of the CBT model, and exemplifies important differences and commonalities of CBT approaches. The overarching principle of CBT interventions is that cognitions causally influence emotional experiences and behaviors. The book reviews recent mediation studies, experimental studies, and neuroimaging studies in affective neuroscience that support the basic model of CBT, as well as those that clarify the mechanisms of treatment change. Additionally, the book explains the interplay of cognition and emotion in CBT, specifies the treatment goals of CBT, discusses the relationship of cognitive models with medical models and associated diagnostic systems, and provides concrete illustrations of important general and disorder-specific considerations of CBT. - Investigates the scientific foundation of CBT - Explores the interplay of emotion and cognition in CBT - Reviews neuroscience studies on the mechanisms of change in CBT - Identifies similarities and differences in CBT approaches for different disorders - Discusses CBT extensions and modifications - Describes computer assisted applications of CBT

This volume collects cutting-edge expert reviews in the oxytocin field and will be of interest to a broad scientific audience ranging from social neuroscience to clinical psychiatry. The role of the neuropeptide oxytocin in social behaviors is one of the earliest and most significant discoveries in social neuroscience. Influential studies in animal models have delineated many of the neural circuits and genetic components that underlie these behaviors. These discoveries have inspired researchers to investigate the effects of oxytocin on brain and behavior in humans and its potential relevance as a treatment for psychiatric disorders including borderline personality disorder and autism and schizophrenia spectrum disorders. In fact, there is no established social psychopharmacology in Psychiatry, and oxytocin can be seen as the first endogenous agent specifically addressing social-cognitive impairment in psychiatric disorders, with animal research suggesting that it could be especially efficient in the early postnatal period. From a human perspective, it is crucial to understand more precisely who can benefit from potential oxytocin-related treatments, which outcome measures will best represent their effects, how they should be administered, and what brain mechanisms are likely involved in mediating their effects. This type of “precision medicine” approach is in line with the research domain criteria defined by the U.S. National Institute of Mental Health.